On the other hand, HER2 is often heterogeneous and associated with other co-existing drivers in gastric cancer (GC), therefore limiting long-term benefit from trastuzumab in most patients with metastatic disease4,11. This evidence concerns the gene ERBB2 and gastric cancer.